OEM

BrainCool AB

Medicon Village, Scheelevagen 2 , 223 81 Lund
Sweden

Telephone +46 727 009454
info@braincool.se

This company is co-exhibitor of
Business Sweden (The Swedish Trade & Invest Council)

Trade fair hall

  • Hall 1 / D18
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 1): stand D18

Fairground map

MEDICA 2016 fairground map: Hall 1

Our range of products

Product categories

  • 01  Electromedical equipment / Medical Technology
  • 01.03  Therapie and physical medicine
  • 01.03.07  Cryotherapy / Cryosurgery equipment

Cryotherapy / Cryosurgery equipment

Our products

Product category: Cryotherapy / Cryosurgery equipment

The products

BRAIN COOLING

•A brain hypothermia device,  for the stroke market – The BrainCool™System

•A brain hypothermia device for the cardiac arrest market – The BrainCool™System ( the same product with a different configuration )

Both product offers a cash flow driven business model.  With the accessories BrainCool Pads® which is used for not more than 1 – 2 patients on a weekly basis.

THE BRAINCOOL™ SYSTEM FOR STROKE
An estimated worldwide market potential of $3 billion annually. 

THE BRAINCOOL™ SYSTEM FOR CARDIAC ARREST
Current annual sales by three major players (Bard / Medivance, Asah Kasei / Zoll and Philips Healthcare) $ 150 million* with an annual growth of 30–40% with a similar market potential as stroke.

THE POLARCAP™ SYSTEM , FOR TREATMENT OF CONCUSSION
With 3.8 million sports-related cases annually in the US.

The PolarCap® System is a portable cooling system with high effect, which will be used to reduce the temperature of the brain in ice hockey players by cooling the scalp and neck via circulating cold fluid in a cap complete with collar.

The product is now being evaluated in a first clinical study in which Malmö Redhawks and yet another Swedish ice hockey team are participating.

In the first quarter of 2016 a subsidiary has been created, IQool Technologies, with a focus on sports medicine with the first business area, treatment of concussions, with the product The PolarCap System.
 
MEDICAL COOLING OF ONCOLOGY
Prevention of oral mucositis (OM), a major severe side effect of cancer treatment – The Cooral™ System

• In 2009, Medicare reimbursed over $40,000 per patient with ulcerative mucositis lesions.

http://www.cancertherapyadvisor.com/oral-mucositis-in-cancer-patients-treatment-update/article/240497/

• GlobalData estimated that the oral mucositis therapeutics market was valued at $813.2m in 2010. Further, the oral mucositis therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 5.2% from $813.2m in 2010 to $1,156.0m in 2017. The growth would be primarily due to the increase in cancer patients, increased rate of chemotherapy and increase in awareness among patients about oral mucositis.

The market for prevention of Oral Mucositis is valued at more than $1 billion annually

THE COORAL™ SYSTEM FOR PREVENTION OF ORAL MUCOSITIS
The Cooral™ product is a single-use cooling oral device, used every time a patient undergoes chemotherapy (or radiation to head and neck) connected to a portable cooling system.
The product has received De Novo 510 k designation and has also now received an EARLY ACCESS PATHWAY with priority review (the strongest fast track in medical devices) and the current Swedish trial is accepted as base for approval by the FDA.

More Less

About us

Company details

BrainCool AB (publ) is a Swedish medical device company, listed since May 2014 on Aktietorget
The business idea is to develop and market patented medical cooling technologies with an initial focus on brain cooling and prevention of oral mucositis.
The vision is to create The Medical Cooling Company with a clear focus on bringing products with high innovation and medical needs to the market. These products will create a de facto standard in their field.

More Less